Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by sgandzaon Feb 28, 2012 12:50pm

241 Views

Post# 19598693

RE: Why?

It's a double edged sword - On the one hand, you put out a PR stating that the permits are expected in 2 weeks and then not deliver, shareholders get frustrated. On the other, don't put out any guidance and the shareholders get frustrated that they are being kept in the dark. I've been on the other side of the coin - waiting and waiting with no news - and it is equally annoying.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity